Business
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up data from Phase 1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC patients to be presented at ASCO 2026 Bill Schelman, M.D., Ph.D., EVP, Clinical Development promoted to Chief Medical Officer, and David Raben, M.D., Chief Medical Officer transitioned to se
About this update from Bicara Therapeutics Inc.
[{"type":"image","alt":"Bicara Therapeutics Inc.","displaySize":"","headline":null,"caption":"Bicara Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hf_5AjJbE0WjKlfEq9Iqwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe","width":300,"height":86},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hf_5AjJbE0WjKlfEq9Iqwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe","width":300,"height":86}},"lazy":false},{"type":"text","content":"Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026","length":182,"tagName":"p"},{"type":"text","content":"Long-term follow-up data from Phase 1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC patients to be presented at ASCO 2026","length":179,"tagName":"p"},{"type":"text","content":"Bill Schelman, M.D., Ph.D., EVP, Clinical Development promoted to Chief Medical Officer, and David Raben, M.D., Chief Medical Officer transitioned to serve as a Senior Executive Advisor to the company","length":200,"tagName":"p"},{"type":"text","content":"Chris Sarchi appointed as Chief Commercial Officer","length":50,"tagName":"p"},{"type":"text","content":"BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX) today announced financial results for the first quarter ended March 31, 2026 and provided a business update.","length":189,"tagName":"p"},{"type":"text","content":"“The first quarter of 2026 reflects strong progress as we work to position ficerafusp alfa as the cornerstone of treatment in HPV-negative head and neck cancer. In addition to advancing our FORTIFI-HN01 pivotal trial, we continued to enroll patients in additional Phase 1b signal-seeking studies as we aim to unlock the full blockbuster potential of ficerafusp alfa. Based on recent FDA discussions, we plan to initiate a randomized study to evaluate a loading and every-three-week maintenance dosing regimen – further differentiating fi...